Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies. The current dominant manufacturing approach for CAR T cells depends on retroviral transduction. With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kath, Jonas, Du, Weijie, Pruene, Alina, Braun, Tobias, Thommandru, Bernice, Turk, Rolf, Sturgeon, Morgan L., Kurgan, Gavin L., Amini, Leila, Stein, Maik, Zittel, Tatiana, Martini, Stefania, Ostendorf, Lennard, Wilhelm, Andreas, Akyüz, Levent, Rehm, Armin, Höpken, Uta E., Pruß, Axel, Künkele, Annette, Jacobi, Ashley M., Volk, Hans-Dieter, Schmueck-Henneresse, Michael, Stripecke, Renata, Reinke, Petra, Wagner, Dimitrios L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062427/
https://www.ncbi.nlm.nih.gov/pubmed/35573047
http://dx.doi.org/10.1016/j.omtm.2022.03.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062427/
https://www.ncbi.nlm.nih.gov/pubmed/35573047
http://dx.doi.org/10.1016/j.omtm.2022.03.018

Ejemplares similares